A recent study from the Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; and Institute for Biomedical Research, University College London, London, UK shows that “Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation.” This study was published in the Apr 23 2014 Nature by Prof Ulrich H. von Andrian, Lorena Riol-Blanco, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Psoriasis: NR2F2 decreases psoriasiform skin inflammaiton via down regulation of its target gene. This study suggests that NR2F2, by increasing the expression of its target gene, it may alleviate the interleukin-23-mediated psoriasiform skin inflammation. Together, this study suggests that pharmacological formulations encompassing “NR2F2 or its activators” may be used to treat psoriasiform skin inflammation.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Molecular therapy for Psoriasis: NR2F2 decreases psoriasiform skin inflammaiton via down regulation of its target gene., 25/Septmber/2014, 06.47 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation